Korean J Urol.  2013 Jul;54(7):477-481.

Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Chronic Bacterial Prostatitis

• Seo Y
• Lee G

Abstract

PURPOSE
Enterococcus faecalis is one of the most common pathogens linked to chronic bacterial prostatitis (CBP). Owing to a limited number of previous studies addressing this topic, we aimed to determine the drug resistance patterns of E. faecalis strains isolated from CBP patients.
MATERIALS AND METHODS
One thousand twenty-one patients visited a single hospital owing to chronic prostatitis for 5 years. Culture specimens were obtained by use of a modified Meares-Stamey method. The minimal inhibitory concentrations of the antimicrobials were assessed by use of the Vitek II microbial identification system as suggested by the Clinical and Laboratory Standards Institute.
RESULTS
Forty-one samples from 41 patients who had significant E. faecalis loads for defining CBP were included in this study. The E. faecalis strains in our study were resistant to penicillin (9.7%), ampicillin (0%), ampicillin/sulbactam (0%), nitrofurantoin (0%), imipenem (0%), vancomycin (0%), teicoplanin (0%), quinupristin/dalfopristin (100%), ciprofloxacin (9.7%), levofloxacin (4.8%), norfloxacin (26.8%), erythromycin (95%), gentamicin (46.3%), tetracycline (97.5%), and trimethoprim/sulfamethoxazole (31.5%), respectively.
CONCLUSIONS
Fluoroquinolones have been the preferred antibiotics for treating CBP. Because of their low rate of drug resistance, fluoroquinolones are suitable therapeutic agents for E. faecalis strains causing CBP in Korea. Even though tetracycline, erythromycin, and trimethoprim/sulfamethoxazole have been prescribed as an empirical antimicrobial therapy for chronic prostatitis, we cannot recommend these drugs for treatment of E. faecalis isolates because of the high rates of drug resistance.

Keyword

Drug resistance; Enterococcus faecalis; Prostatitis

MeSH Terms

Ampicillin
Anti-Bacterial Agents
Ciprofloxacin
Drug Resistance
Enterococcus
Enterococcus faecalis
Erythromycin
Fluoroquinolones
Gentamicins
Humans
Imipenem
Korea
Nitrofurantoin
Norfloxacin
Ofloxacin
Penicillins
Prostatitis
Teicoplanin
Tetracycline
Vancomycin
Ampicillin
Anti-Bacterial Agents
Ciprofloxacin
Erythromycin
Fluoroquinolones
Gentamicins
Imipenem
Nitrofurantoin
Norfloxacin
Ofloxacin
Penicillins
Teicoplanin
Tetracycline
Vancomycin

Reference

1. Naber KG, Busch W, Focht J. The German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. Int J Antimicrob Agents. 2000. 14:143–149.

2. Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2010. 106:1252–1263.

3. Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician. 2010. 82:397–406.

4. Meares EM Jr. Bacterial prostatitis vs "prostatosis". A clinical and bacteriological study. JAMA. 1973. 224:1372–1375.

5. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991. 19:Suppl 3. S119–S125.

6. Cai T, Mazzoli S, Meacci F, Boddi V, Mondaini N, Malossini G, et al. Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol. 2011. 49:448–454.

7. Panagopoulos P, Antoniadou A, Kanellakopoulou K, Tsiodras S, Katsarolis I, Papadopoulos A, et al. Fluoroquinolone treatment of chronic bacterial prostatitis: a prospective cohort study. J Chemother. 2009. 21:317–321.

8. Milingos S, Creatsas G, Messinis J, Lolis D, Kaskarelis D. Treatment of chronic prostatitis by consecutive per os administration of doxycycline, sulfamethoxazole/trimethoprim, and cephalexin. Int J Clin Pharmacol Ther Toxicol. 1983. 21:301–305.

9. Baumuller A. Antimicrobials for the treatment of bacterial prostatitis. Historical developments and current trends. Scand J Urol Nephrol Suppl. 1987. 104:97–99.

10. Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2012. 110:1014–1022.

11. Dalhoff A, Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol Infect Dis. 1988. 7:438–439.

12. Lee G, Cho YH, Shim BS, Lee SD. Risk factors for antimicrobial resistance among the Escherichia coli strains isolated from Korean patients with acute uncomplicated cystitis: a prospective and nationwide study. J Korean Med Sci. 2010. 25:1205–1209.

13. Jang WH, Yoo DH, Park SW. Prevalence of and risk factors for levofloxacin-resistant E. coli isolated from outpatients with urinary tract infection. Korean J Urol. 2011. 52:554–559.

14. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999. 282:236–237.

15. Nickel JC. Prostatitis: evolving management strategies. Urol Clin North Am. 1999. 26:737–751.

16. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968. 5:492–518.

17. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology. 2005. 66:721–725.

18. Lee KS, Choi JD. Chronic prostatitis: approaches for best management. Korean J Urol. 2012. 53:69–77.

19. Nickel JC, Downey J, Clark J, Ceri H, Olson M. Antibiotic pharmacokinetics in the inflamed prostate. J Urol. 1995. 153:527–529.

20. Chen J, Chen RR, Huang HS. Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate. J Formos Med Assoc. 2001. 100:548–552.

21. Grabe M, Forsgren A, Bjork T. Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection. Eur J Clin Microbiol. 1986. 5:211–212.

22. Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother. 2000. 44:2046–2051.

23. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003. 49:269–279.

24. Dunn BL, Stamey TA. Antibacterial concentrations in prostatic fluid. 1. Nitrofurantoin. J Urol. 1967. 97:505–507.

25. Dyderski S, Sokołowski W. Gentamicin level in the prostate and its pharmacokinetics in patients with benign prostatic hypertrophy. Pol Tyg Lek. 1990. 45:517–519.

26. Oosterlinck W, Defoort R, Renders G. The concentration of sulphamethoxazole and trimethoprim in human prostate gland. Br J Urol. 1975. 47:301–304.

27. Schaeffer AJ, Darras FS. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol. 1990. 144:690–693.

28. Fowler JE Jr. Antimicrobial therapy for bacterial and nonbacterial prostatitis. Urology. 2002. 60:6 Suppl. 24–26.

29. Sharer WC, Fair WR. The pharmacokinetics of antibiotic diffusion in chronic bacterial prostatitis. Prostate. 1982. 3:139–148.

30. Quinones D, Goni P, Rubio MC, Duran E, Gomez-Lus R. Enterococci spp. isolated from Cuba: species frequency of occurrence and antimicrobial susceptibility profile. Diagn Microbiol Infect Dis. 2005. 51:63–67.